Sagar Lonial, MD, FACP, FASCO

Articles

EHA 2025 Insights: Emerging Developments and Future Perspectives for the Multiple Myeloma Treatment Landscape

August 20th 2025

Panelists discuss how emerging combination therapies such as bispecific antibodies with chimeric antigen receptor (CAR) T cells show promising response rates in patients with heavily refractory disease, while highlighting the ongoing unmet need to improve treatment access and educate community practices on advanced therapies.

Expanding Access to Bispecifics In R/R MM: Keys To Building Successful Outpatient Step-Up Dosing Models

August 13th 2025

Panelists discuss how successful outpatient bispecific programs require institutional champions, 24-hour on-call support, comprehensive staff education, and preemptive tocilizumab dosing to achieve readmission rates of only 3%.

Bispecific Step-Up Dosing Models in R/R MM: Real-World Protocols and Institutional Practices

August 13th 2025

Panelists discuss how institutions have evolved from inpatient to hybrid and outpatient step-up dosing models for bispecific antibodies, using preemptive tocilizumab and patient education to reduce cytokine release syndrome rates to under 20%.

Sequencing Strategies For R/R MM: Choosing Between BCMA- and GPRC5D-Targeting Agents

August 6th 2025

Panelists discuss how to sequence B-cell maturation antigen (BCMA)– and GPRC5D-targeting bispecific antibodies based on patient factors, with BCMA agents having higher infection risk and GPRC5D agents causing taste changes and weight loss.

EHA 2025 Insights: Real-World Data Updates On Teclistamab and Talquetamab In Advanced R/R MM

August 6th 2025

Panelists discuss how real-world data studies such as Real-TEC provide comparative effectiveness evidence for teclistamab and talquetamab, showing 60% response rates and the potential for treatment spacing without compromising efficacy.

Identifying Appropriate Candidates for Bispecific Antibodies In “Hard-to-Treat” R/R MM

July 30th 2025

Panelists discuss how to identify patients with hard-to-treat relapsed/refractory multiple myeloma (R/R MM) with aggressive disease who need rapid disease control, making them ideal candidates for off-the-shelf bispecific antibodies rather than chimeric antigen receptor (CAR) T therapy.

EHA 2025 Insights: DREAMM-7 and DREAMM-8 Trial Updates on Belantamab-Based Regimens for R/R MM

July 30th 2025

Panelists discuss how belantamab mafodotin shows added benefit in high-risk cytogenetic subgroups and may provide a more accessible B-cell maturation antigen (BCMA)–targeting option for community practices, though questions remain about optimal sequencing and impact on future therapies.

EHA 2025 Insights: CARTITUDE-1 Trial Updates on Long-Term Efficacy and Safety of CAR T in Late R/R MM

July 23rd 2025

Panelists discuss how the CARTITUDE-1 trial’s 5-year follow-up data demonstrate that approximately one-third of heavily pretreated patients with multiple myeloma (MM) remain drug free and myeloma free, while addressing safety concerns and risk mitigation strategies for CAR T therapy.

Identifying The Ideal Candidate for CAR T in Late R/R Multiple Myeloma

July 23rd 2025

Panelists discuss how age should not be a barrier to chimeric antigen receptor (CAR) T therapy, emphasizing that organ function and disease control during bridging are more important factors, while acknowledging system-based capacity limitations for widespread CAR T implementation.

EHA 2025 Insights: CARTITUDE-4 Trial Updates On CAR T in Early R/R MM

July 16th 2025

Panelists discuss how chimeric antigen receptor (CAR) T therapy should be considered earlier in the treatment course, particularly for functionally high-risk patients who relapse within 12 to 18 months, young patients, and older patients who could benefit from treatment-free intervals.

EHA 2025 Insights: IMROZ Trial Updates On Isatuximab-Based Regimens for Transplant-Ineligible High-Risk Patients In NDMM

July 16th 2025

Panelists discuss how updated data from the IMROZ trial confirm the benefit of adding isatuximab to VRd in transplant-ineligible patients, achieving doubled sustained MRD negativity rates, while noting that daratumumab and isatuximab appear interchangeable in clinical practice.

EHA 2025 Insights: Subgroup Analysis of Transplant-Ineligible Patients With NDMM in the CEPHEUS Trial

July 9th 2025

Panelists discuss how truly transplant-ineligible frail patients in CEPHEUS still benefited from quadruplet therapy despite increased infection risks and provide practical tips for community oncologists on implementing CD38 antibody–containing regimens.

EHA 2025 Insights: CEPHEUS Trial Updates on Daratumumab-Based Regimens for Transplant-Ineligible Patients With High-Risk Cytogenetics in NDMM

July 9th 2025

Panelists discuss how the CEPHEUS trial data showed that quadruplet therapy benefits primarily standard-risk patients rather than high-risk cytogenetic groups in transplant-ineligible populations, contrary to expectations.

EHA 2025 Insights: ADVANCE and PERSEUS Trial Updates on Daratumumab-Based Regimens for Transplant-Eligible Patients With NDMM

June 30th 2025

Panelists discuss how recent trial data from ADVANCE and PERSEUS demonstrate that quadruplet regimens with daratumumab plus transplant achieve superior minimal residual disease (MRD) negativity rates compared with triplet regimens but emphasize the importance of sustained MRD negativity for long-term outcomes.

Transplant Eligibility Considerations in Patients With Newly Diagnosed Multiple Myeloma

June 30th 2025

Panelists discuss how transplant eligibility should be viewed as a continuum based on frailty rather than a binary decision, with most patients collecting stem cells but only about 20% receiving delayed transplants.